Trade Report: Today: Aratana Therapeutics Inc. (PETX) Given Average Recommendation of “Buy” from Brokerages

Today: Aratana Therapeutics Inc. (PETX) Given Average Recommendation of “Buy” from Brokerages

Aratana Therapeutics Inc. (NASDAQ:PETX) has been assigned an average recommendation of “Buy” from the eight research firms that are covering the stock. Two analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $11.00.

A number of analysts have recently commented on the company. Zacks Investment Research cut Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 22nd. Jefferies Group reaffirmed a “buy” rating and issued a $11.00 price objective (down from $13.00) on shares of Aratana Therapeutics in a research report on Friday, November 18th. Lake Street Capital reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Aratana Therapeutics in a research report on Tuesday, September 6th. William Blair reaffirmed an “outperform” rating on shares of Aratana Therapeutics in a research report on Wednesday, August 17th. Finally, Barclays PLC lowered their price objective on Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating on the stock in a research report on Thursday, August 11th.

In other news, insider Ernst Heinen sold 10,000 shares of the company’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $10.00, for a total value of $100,000.00. Following the completion of the sale, the insider now directly owns 115,494 shares in the company, valued at approximately $1,154,940. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Craig A. Tooman sold 30,000 shares of the company’s stock in a transaction on Friday, September 9th. The stock was sold at an average price of $9.25, for a total value of $277,500.00. Following the completion of the sale, the insider now owns 72,424 shares of the company’s stock, valued at $669,922. The disclosure for this sale can be found here. Insiders own 6.70% of the company’s stock.

Large investors have recently bought and sold shares of the company. Blair William & Co. IL raised its stake in Aratana Therapeutics by 9.8% in the second quarter. Blair William & Co. IL now owns 603,652 shares of the biopharmaceutical company’s stock valued at $3,815,000 after buying an additional 53,703 shares during the period. California State Teachers Retirement System raised its stake in Aratana Therapeutics by 9.7% in the second quarter. California State Teachers Retirement System now owns 69,941 shares of the biopharmaceutical company’s stock valued at $442,000 after buying an additional 6,211 shares during the period. General American Investors Co. Inc. bought a new stake in Aratana Therapeutics during the second quarter valued at approximately $2,604,000. Tocqueville Asset Management L.P. raised its stake in Aratana Therapeutics by 51.5% in the third quarter. Tocqueville Asset Management L.P. now owns 50,000 shares of the biopharmaceutical company’s stock valued at $468,000 after buying an additional 17,000 shares during the period. Finally, First Light Asset Management LLC raised its stake in Aratana Therapeutics by 52.9% in the second quarter. First Light Asset Management LLC now owns 684,921 shares of the biopharmaceutical company’s stock valued at $4,329,000 after buying an additional 236,915 shares during the period. Hedge funds and other institutional investors own 77.37% of the company’s stock.

Aratana Therapeutics (NASDAQ:PETX) traded down 1.56% during mid-day trading on Monday, reaching $7.57. The company’s stock had a trading volume of 157,990 shares. The firm’s market cap is $280.42 million. The company has a 50-day moving average price of $8.26 and a 200-day moving average price of $7.85. Aratana Therapeutics has a 12-month low of $2.56 and a 12-month high of $10.73.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.10. Aratana Therapeutics had a negative return on equity of 19.87% and a negative net margin of 60.32%. During the same period in the previous year, the company posted ($1.58) EPS. On average, equities research analysts expect that Aratana Therapeutics will post ($0.72) earnings per share for the current year.

Related posts

Leave a Comment